Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
ERS 2023 Conference
- Home
- ERS Conference 2023
OXC-201 in IPF
Oxcia’s OXC-201 is a small molecule inhibitor of OGG1, a potential breakthrough for treating IPF (idiopathic pulmonary fibrosis), other fibrotic conditions, and inflammatory diseases while providing a unique mechanism of action that affects multiple signaling pathways and pathological processes associated with IPF, potentially preventing further lung damage.
Our Recent Articles
Types / Technology
Indications
Title
OXC-201 in IPF
Summary
Oxcia’s OXC-201 is a small molecule inhibitor of OGG1, a potential breakthrough for treating IPF (idiopathic pulmonary fibrosis), other fibrotic conditions, and inflammatory diseases while providing a unique mechanism of action that affects multiple signaling pathways and pathological processes associated with IPF, potentially preventing further lung damage.
Article Type
Clinical Trials
Title
Treprostinil palmitil data presented for PH-ILD
Summary
Current treatment for PH-ILD involves the use of drugs like bosentan (an endothelin receptor antagonist), sildenafil (a phosphodiesterase-5 inhibitor), and epoprostenol (a prostacyclin analog) to relieve pulmonary vascular constriction and enhance lung blood flow, ultimately reducing elevated pulmonary artery pressure.
Article Type
Clinical Trials
Title
Efzofitimod's Victory
Summary
aTyr, working to develop a new class of drugs based on the extracellular biology of tRNA synthetase, Efzofitimod, presented a post-hoc analysis of the Phase Ib/IIa study in pulmonary sarcoidosis at the European Respiratory Society (ERS) at International conference taking place in Milan, Italy from September 9 to 13, 2023.
Article Type
Clinical Trials
Title
Brensocatib’s Breakthrough: A Ray of Hope for Cystic Fibrosis and Beyond at ERS International Congress 2023
Summary
Insmed Inc.’s creation, Brensocatib, a small oral molecule acting as a reversible inhibitor of dipeptidyl peptidase 1 (DPP1), holds substantial promise for patients with both CF and NCFBE. DPP1 is an enzyme accountable for triggering neutrophil serine proteases (NSPs) in neutrophils, pivotal white blood cells central to infection defense and inflammation regulation.
Article Type
Clinical Trials
Title
ERS 2023 Reveals Efzofitimod Data
Summary
In a monumental stride toward combating Systemic Sclerosis-Interstitial Lung Disease (SSC-ILD), aTyr Pharma, Inc. unveiled the data related to its first-in-class drug, Efzofitimod, at the European Respiratory Society (ERS) International Congress 2023.
Article Type
Clinical Trials
Title
Arrowhead’s RNAi Candidate at ERS 2023
Summary
As per DelveInsight’s analysis, the estimated market size for asthma in 2022 stood at approximately USD 18,460 million. However, with the introduction of new emerging drugs, the market is expected to experience substantial growth.
Article Type
Clinical Trials
Case Studies
Partner Identification
Partners Identification for client's early-stage oncology-based clinical product for late-stage clinical development & commercialization.
Pipeline Assessment
Assessment of pipeline activities around the client's area of interest to support strategic decisions.
Epidemiology Assessment
In-depth assessment to understand the epidemiological scenario of Cutaneous Squamous Cell Carcinoma
Market Assessment
Evaluation of the oncological market potential of the asset gained through the acquisition and collaborations
Product Assessment
Performance evaluation of new assets based on the Lead and Lag KPI
Newsletter and Whitepapers
Gout Market is Anticipated to Expand Due to Active as well as Emerging Pipeline Therapies
Gout is a chronic disease caused by the deposition of monosodium urate (MSU) crystals in joints. It typically presents as an acute, self-limiting inflammatory monoarthritis that affects the joints of the lower limb. Various symptoms of Gout include intense joint pain, joint swelling, stiffness, tenderness, even to light touch, such as from a bedsheet, heat in the affected area, and joint redness.
-Market-Market.png&w=3840&q=75)
Get Expert Consultation Now!
Our extensive history and deep knowledge in the field of respiratory health make us an ideal collaborator for addressing your urgent business challenges.
We possess a comprehensive grasp of the respiratory industry's landscape, a detailed insight into market trends, and a keen awareness of marketing intricacies. These strengths can empower you to develop a remarkably effective strategy for future success.
Feel free to reach out to us for a conversation about potential collaboration and to explore the extensive value we can bring to your endeavors.
Delivering value through our expansive service offerings
Considering the rapidly evolving nature of the respiratory therapy field, it is crucial to establish a competitive advantage for your business from the outset. With our extensive range of consulting solutions and market research services, we are ideally positioned to guide you in overcoming challenges and capitalizing on your strengths and opportunities.
Our expertise is geared towards providing actionable insights for gaining a competitive edge and crafting impactful business growth strategies. Join us on this journey to unlock opportunities and avoid potential pitfalls, as we simplify the process of maximizing your return on investment through our expert guidance.
Partner with us to discover which assets might offer the most potential in the future
Our comprehensive 11-year projection offers valuable insights to inform strategic decision-making for a successful market entry.
Access our research prowess for timely insights that enhance your business decisions
We offer support in maneuvering through the challenging drug development process with our insightful intelligence assessments